查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584715

活性藥物成分市場：按類型、合成、製造商、治療應用分類 - 全球預測 2025-2030

Active Pharmaceutical Ingredients Market by Type, Synthesis, Manufacturer, Therapeutic Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年活性藥物成分市值為1527.7億美元，預計2024年將達到1643.4億美元，複合年成長率為7.88%，到2030年將達到2599.7億美元。

活性藥物成分 (API) 是藥物的重要組成部分，可提供其預期效果。原料藥的範圍涵蓋藥物製劑的需求、疾病治療的廣泛應用以及製藥、生物技術和契約製造組織的最終用途。慢性病新興市場的擴大、老年人口的增加以及藥物開發技術的進步是原料藥市場的關鍵成長要素。生技藥品的日益普及和特種藥物需求的激增是值得注意的機會。專利到期、學名藥增加以及對個人化醫療的關注等因素進一步推動市場發展。強調藥物功效和安全性的監管要求正在推動製造流程的創新並創造機會，特別是在綠色化學和生物技術進步方面。

主要市場統計
基準年[2023] 1527.7億美元
預測年份 [2024] 1643.4億美元
預測年份 [2030] 2599.7億美元
複合年成長率（%） 7.88%

然而，市場並非沒有挑戰。嚴格的法律規範、高製造成本和複雜的製造流程是主要障礙。原料供應中斷的威脅，特別是由於地緣政治緊張局勢和對有限供應商的依賴，可能會阻礙市場成長。此外，每個地區的合規規範都在不斷發展，需要不斷調整，這可能會影響公司的業務效率。為了抓住新機遇，企業應該投資開發永續和環保的製造程序，利用人工智慧和機器學習來最佳化生產，並加強品管。對生物相似藥和新型藥物輸送系統的追求提供了競爭優勢。

原料藥市場高度活躍，其特點是旨在擴大產品系列和推廣範圍的策略聯盟和合併。對研究和開發的關注，特別是核酸和胜肽等非傳統 API，代表了一個有前途的創新領域。雖然該行業是技術密集型行業，但它的繁榮也依賴對不斷變化的法規和市場需求的適應，並且需要採取積極主動的風險管理和生產適應性方法以維持長期成長。

市場動態：快速發展的活性藥物成分市場的關鍵市場洞察

供需的動態交互作用正在改變活性藥物成分市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 製藥公司活性化研發活動
    • 政府對先進醫藥製造技術的支持
    • CDMO增加投資以增強藥品生產能力
  • 市場限制因素
    • 先進 API 技術帶來的高成本
  • 市場機會
    • 活性藥物成分技術的技術進步
    • 採用微粉化技術開發新治療藥物
  • 市場挑戰
    • 實現和維持所需粒徑分佈涉及的技術複雜性

波特五力：駕馭活性藥物成分市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解原料藥市場的外部影響

外部宏觀環境因素在塑造活性藥物成分市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解藥物活性成分市場的競爭狀況

對活性藥物成分市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣活性藥物成分市場供應商的績效評估

FPNV 定位矩陣是評估活性藥物組成市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

戰略分析與推薦活性藥物成分市場成功圖表

對於旨在加強在全球市場的影響力的公司來說，活性藥物成分市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥公司研發活動增加
      • 政府對先進醫藥製造技術的支持
      • CDMO增加投資以增強藥品生產能力
    • 抑制因素
      • 先進 API 技術帶來的高成本
    • 機會
      • 活性藥物成分技術的技術進步
      • 採用微粉化技術開發新藥
    • 任務
      • 與實現和維持所需粒徑分佈相關的技術複雜性
  • 市場區隔分析
    • 類型：透過降低研發成本提高通用 API 的可訪問性
    • 治療應用：糖尿病的全球盛行率推動了活性藥物成分的研究和開發
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章活性藥物成分市場：依類型

  • 常見的活性藥物成分
  • 創新活性藥物成分

第7章活性藥物成分市場：透過合成

  • 生物技術藥物活性成分
  • 合成藥物活性成分

第8章活性藥物成分市場：依製造商分類

  • 專屬式API 製造商
  • 商家 API 製造商

第9章活性藥物成分市場：依治療應用分類

  • 心血管疾病
  • 傳染病
  • 糖尿病
  • 腫瘤學
  • 疼痛管理
  • 呼吸系統疾病

第10章美洲原料藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太原料藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲原料藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 禮來公司 (Eli Lilly) 投資創紀錄的 90 億美元，以擴大糖尿病和減肥藥的 API 生產
    • 美國合作促進密蘇裡州新腫瘤設施生產膠質神經膠母細胞瘤必需藥物
    • Noramco 集團加強北美藥品供應鏈
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • API Pharma Tech
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • BASF SE
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd
  • ELI Lilly and Company
  • F. Hoffmann-La Roche AG
  • Glaxosmithkline PLC
  • Lonza Group Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
Product Code: MRR-430D42AA0F7B

The Active Pharmaceutical Ingredients Market was valued at USD 152.77 billion in 2023, expected to reach USD 164.34 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 259.97 billion by 2030.

Active Pharmaceutical Ingredients (APIs) form the critical components in pharmaceuticals, responsible for the intended effects of drugs. The scope of APIs encompasses their necessity in drug formulation, wide-ranging applications across disease treatments, and end-use in pharmaceuticals, biotechnology, and contract manufacturing organizations. The growing prevalence of chronic diseases, increasing geriatric population, and advancements in drug development technologies are pivotal growth factors in the API market. The rising adoption of biologics and the surge in demand for specialty medicines present notable opportunities. Factors such as patent expirations, increased generic drug production, and a focus on personalized medicine further bolster market advancements. Regulatory mandates that stress drug efficacy and safety are driving innovations in manufacturing processes, fostering opportunities especially within green chemistry and biotechnological advancements.

KEY MARKET STATISTICS
Base Year [2023] USD 152.77 billion
Estimated Year [2024] USD 164.34 billion
Forecast Year [2030] USD 259.97 billion
CAGR (%) 7.88%

However, the market is not devoid of challenges. Stringent regulatory frameworks, high production costs, and complex manufacturing processes pose significant hurdles. The threat of raw material supply disruptions, particularly due to geopolitical tensions and dependency on a limited number of suppliers, can hinder market growth. Moreover, evolving compliance norms across regions necessitate constant adaptation, potentially impacting firms' operational efficiencies. To capitalize on emerging opportunities, companies should invest in the development of sustainable and eco-friendly manufacturing processes, leveraging AI and machine learning to optimize production and enhance quality control. Pursuing biosimilars and novel drug delivery systems can offer competitive advantages.

The API market is highly dynamic, characterized by strategic collaborations and mergers aimed at expanding product portfolios and geographical outreach. Emphasis on research and development, particularly in non-traditional APIs like nucleic acids and peptides, marks a promising area for innovation. While being technology-intensive, the industry also thrives on adaptability to regulatory changes and market demands, making it crucial for players to maintain a proactive approach in risk management and production adaptability to sustain long-term growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients Market

The Active Pharmaceutical Ingredients Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing research & development activities by pharmaceutical companies
    • Government support for advanced pharmaceutical manufacturing techniques
    • Rising investments to enhance drug manufacturing capabilities by CDMOs
  • Market Restraints
    • High cost associated with advanced API technologies
  • Market Opportunities
    • Technological advancements in active pharmaceutical ingredients techniques
    • Adoption of micronization techniques to develop novel drug therapeutics
  • Market Challenges
    • Technical complexity associated with achieving and maintaining the desired particle size distribution

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients Market

A detailed market share analysis in the Active Pharmaceutical Ingredients Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients Market

A strategic analysis of the Active Pharmaceutical Ingredients Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., API Pharma Tech, AstraZeneca PLC, Aurobindo Pharma Limited, BASF SE, BDR Pharmaceuticals Internationals Pvt. Ltd., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cipla, Inc., Dr. Reddy's Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC, Lonza Group Ltd., Lupin Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients.
  • Based on Synthesis, market is studied across Biotech Active Pharmaceutical Ingredients and Synthetic Active Pharmaceutical Ingredients.
  • Based on Manufacturer, market is studied across Captive API Manufacturers and Merchant API Manufacturers.
  • Based on Therapeutic Application, market is studied across Cardiovascular Diseases, Communicable Diseases, Diabetes, Oncology, Pain Management, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing research & development activities by pharmaceutical companies
      • 5.1.1.2. Government support for advanced pharmaceutical manufacturing techniques
      • 5.1.1.3. Rising investments to enhance drug manufacturing capabilities by CDMOs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced API technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in active pharmaceutical ingredients techniques
      • 5.1.3.2. Adoption of micronization techniques to develop novel drug therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Technical complexity associated with achieving and maintaining the desired particle size distribution
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing accessibility of generic APIs due to eliminated R&D expenses
    • 5.2.2. Therapeutic Application: Increasing prevalence of diabetes globally boost the R&D for active pharmaceutical ingredients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients Market, by Type

  • 6.1. Introduction
  • 6.2. Generic Active Pharmaceutical Ingredients
  • 6.3. Innovative Active Pharmaceutical Ingredients

7. Active Pharmaceutical Ingredients Market, by Synthesis

  • 7.1. Introduction
  • 7.2. Biotech Active Pharmaceutical Ingredients
  • 7.3. Synthetic Active Pharmaceutical Ingredients

8. Active Pharmaceutical Ingredients Market, by Manufacturer

  • 8.1. Introduction
  • 8.2. Captive API Manufacturers
  • 8.3. Merchant API Manufacturers

9. Active Pharmaceutical Ingredients Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Diseases
  • 9.3. Communicable Diseases
  • 9.4. Diabetes
  • 9.5. Oncology
  • 9.6. Pain Management
  • 9.7. Respiratory Diseases

10. Americas Active Pharmaceutical Ingredients Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Active Pharmaceutical Ingredients Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Active Pharmaceutical Ingredients Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Eli Lilly's Record-Breaking USD 9 Billion Investment to Boost API Manufacturing for Diabetes and Obesity Treatments
    • 13.3.2. United States Collaboration Enhances Production of Essential Glioblastoma Drug with New Oncology Suite in Missouri
    • 13.3.3. Noramco Group Strengthening North America's Pharmaceutical Supply Chain
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. API Pharma Tech
  • 3. AstraZeneca PLC
  • 4. Aurobindo Pharma Limited
  • 5. BASF SE
  • 6. BDR Pharmaceuticals Internationals Pvt. Ltd.
  • 7. Bristol-Myers Squibb Company
  • 8. C.H. Boehringer Sohn AG & Co. KG
  • 9. Cipla, Inc.
  • 10. Dr. Reddy's Laboratories Ltd
  • 11. ELI Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Glaxosmithkline PLC
  • 14. Lonza Group Ltd.
  • 15. Lupin Ltd.
  • 16. Merck & Co., Inc.
  • 17. Novartis International AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Sun Pharmaceutical Industries Ltd
  • 21. Teva Pharmaceutical Industries Ltd
  • 22. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023